Table 2.
Odds Ratios (OR) and 95% Confidence Intervals for the Selected Proteins With Regards to Their Association With Incident Heart Failure After Adjustment for the Matching Variables and Correction for Multiple Comparisons in Both Discovery and Replication Sets
| Protein Name | Discovery | Replication | ||||
|---|---|---|---|---|---|---|
| OR | (95% CI) | P Value | OR | (95% CI) | P Value | |
| BNP | 1.62 | (1.42–1.86) | <0.0001 | 1.73 | (1.50–2.01) | <0.0001 |
| NT-proBNP | 1.74 | (1.46–2.06) | <0.0001 | 2.00 | (1.64–2.44) | <0.0001 |
| TRAILR2 | 3.26 | (2.32–4.60) | <0.0001 | 3.22 | (2.21–4.69) | <0.0001 |
| TNFRSF13B | 1.74 | (1.34–2.24) | <0.0001 | 2.61 | (1.82–3.74) | <0.0001 |
| GAL9 | 2.96 | (1.95–4.49) | <0.0001 | 3.14 | (2.01–4.91) | <0.0001 |
| FGF23 | 1.70 | (1.40–2.07) | <0.0001 | 1.84 | (1.44–2.36) | <0.0001 |
| TNFRSF10A | 2.63 | (1.88–3.69) | <0.0001 | 2.56 | (1.74–3.77) | <0.0001 |
| REN | 1.31 | (1.11–1.55) | 0.0018 | 1.54 | (1.29–1.85) | <0.0001 |
| TNFRSF11A | 2.09 | (1.61–2.72) | <0.0001 | 1.95 | (1.47–2.59) | <0.0001 |
| GDF-15 | 2.74 | (2.08–3.61) | <0.0001 | 1.89 | (1.44–2.47) | <0.0001 |
| FABP4 | 1.82 | (1.51–2.19) | <0.0001 | 1.57 | (1.29–1.92) | <0.0001 |
| SLAMF7 | 1.55 | (1.26–1.91) | <0.0001 | 2.16 | (1.52–3.06) | <0.0001 |
| CCL16 | 1.47 | (1.21–1.79) | <0.0001 | 1.72 | (1.34–2.22) | <0.0001 |
| TWEAK | 0.51 | (0.36–0.73) | 0.0003 | 0.53 | (0.39–0.71) | <0.0001 |
| KIM1 | 1.41 | (1.19–1.68) | <0.0001 | 1.51 | (1.23–1.84) | <0.0001 |
| CD4 | 2.06 | (1.49–2.85) | <0.0001 | 2.17 | (1.49–3.16) | <0.0001 |
| VSIG2 | 1.43 | (1.14–1.81) | 0.0025 | 1.76 | (1.33–2.32) | <0.0001 |
| PON3 | 0.71 | (0.58–0.87) | 0.0011 | 0.64 | (0.51–0.80) | <0.0001 |
| PLGF | 2.17 | (1.54–3.06) | <0.0001 | 1.95 | (1.38–2.75) | 0.0002 |
| MMP-12 | 1.64 | (1.32–2.03) | <0.0001 | 1.54 | (1.23–1.92) | 0.0002 |
| ADM | 2.56 | (1.82–3.59) | <0.0001 | 1.80 | (1.32–2.45) | 0.0002 |
| RARRES2 | 3.33 | (2.02–5.51) | <0.0001 | 2.05 | (1.38–3.05) | 0.0004 |
| CEACAM8 | 1.51 | (1.22–1.86) | 0.0001 | 1.49 | (1.19–1.86) | 0.0005 |
| SLAMF1 | 1.44 | (1.17–1.76) | 0.0005 | 1.62 | (1.23–2.13) | 0.0005 |
| TNFR1 | 2.40 | (1.75–3.28) | <0.0001 | 1.63 | (1.23–2.16) | 0.0007 |
| AGRP | 1.82 | (1.38–2.40) | <0.0001 | 1.90 | (1.31–2.76) | 0.0007 |
| TNFR2 | 2.11 | (1.58–2.82) | <0.0001 | 1.55 | (1.20–2.00) | 0.0008 |
| IGFBP7 | 1.66 | (1.24–2.23) | 0.0006 | 1.60 | (1.21–2.11) | 0.0010 |
| UPAR | 2.70 | (1.94–3.75) | <0.0001 | 1.67 | (1.23–2.28) | 0.0011 |
| PAR1 | 1.86 | (1.33–2.60) | 0.0003 | 1.74 | (1.24–2.45) | 0.0014 |
| PLC | 2.26 | (1.59–3.21) | <0.0001 | 1.76 | (1.24–2.49) | 0.0015 |
| ACE2 | 1.60 | (1.27–2.02) | <0.0001 | 1.52 | (1.17–1.98) | 0.0016 |
| IL-16 | 1.54 | (1.20–1.97) | 0.0007 | 1.46 | (1.15–1.86) | 0.0019 |
| TFF3 | 1.61 | (1.32–1.95) | <0.0001 | 1.45 | (1.15–1.84) | 0.0019 |
| OPN | 2.00 | (1.52–2.63) | <0.0001 | 1.50 | (1.16–1.95) | 0.0021 |
| SPON2 | 2.86 | (1.50–5.48) | 0.0015 | 2.40 | (1.36–4.25) | 0.0026 |
| IL4RA | 1.52 | (1.15–2.02) | 0.0033 | 1.62 | (1.18–2.22) | 0.0029 |
| TNFRSF14 | 2.09 | (1.55–2.82) | <0.0001 | 1.52 | (1.15–2.01) | 0.0034 |
ACE2 indicates angiotensin-converting enzyme 2; ADM, adrenomedullin; AGRP, agouti-related protein; BNP, brain natriuretic peptide; CCL16, C-C motif chemokine 16; CD4, T-cell surface glycoprotein CD4; CEACAM8, carcinoembryonic antigen-related cell adhesion molecule 8; FABP4, fatty acid-binding protein; FGF23, fibroblast growth factor 23; GAL9, galectin 9; GDF-15, growth/differentiation factor 15; IGFBP7, insulin-like growth factor-binding protein 7; IL-16, pro-interleukin-16; IL4RA, interleukin 4 receptor subunit alpha; KIM1, kidney injury molecule 1; MMP-12, matrix metalloproteinase 12; NT-proBNP, N-terminal pro-B-type natriuretic peptide; OPN, osteopontin; PAR1, proteinase-activated receptor 1; PLC, perlecan; PLGF, placenta growth factor; PON3, paraoxonase; RARRES2, retinoic acid receptor responder protein 2; REN, renin; SLAMF1, signaling lymphocytic activation molecule; SLAMF7, SLAM family member 7; SPON2, spondin-2; TFF3, trefoil factor 3; TNFR1, tumor necrosis factor receptor 1; TNFR2, tumor necrosis factor receptor 2; TNFRSF10A, tumor necrosis factor receptor superfamily member 10A; TNFRSF11A, tumor necrosis factor receptor superfamily member 11A; TNFRSF13B, tumor necrosis factor receptor superfamily member 13B; TNFRSF14, tumor necrosis factor receptor superfamily member 14; TRAILR2, TNF-related apoptosis-inducing ligand receptor 2; TWEAK, tumor necrosis factor (ligand) superfamily, member 12; UPAR, urokinase plasminogen activator surface receptor; and VSIG2, v-set and immunoglobulin domain-containing protein 2.